StocksMedium•11 November 2026•
1 min read
BridgeBio Oncology Shares Jump 18% Despite Analyst Price Target Cuts
Key Facts
1BridgeBio Oncology beat Q3 loss estimates, causing shares to jump 18%.
2Analysts cut price targets for the stock to a range of $9 to $15 despite the positive price action.
BridgeBio Oncology reported Q3 losses that were narrower than analyst estimates, causing the company's shares to jump 18%. Benzinga reported that the positive price action followed financial results that beat initial loss expectations for the period.
Analysts lowered their price targets for BridgeBio Oncology to a range of $9 to $15 despite the recent rally in the share price. These revisions reflect updated long-term valuation models following the release of the Q3 2026 results.